glp-1 drugs thyroid cancer agonist like Ozempic do not increase risk Study Assuages Thyroid Cancer Fears

obesity patients currently receiving prescription GLP-1 anti-obesity medication

Transdermal estrogen does not carry this risk

If needle phobia is a particular issue, discussion of options that have the needle hidden and/or have a pre-attached needle, which require minimal handling by the patient, could be considered

STEP 1 (2021) found that over 68 weeks, more than half of participants given weekly semaglutide achieved at least 15% weight loss, compared with around 5% in the control group

Its ability to reduce hepatic glucose production, improve insulin sensitivity, and offer weight neutrality or modest loss has made it a go-to for clinicians